Fig. 6

Purine metabolism is upregulated in Mfn1^−/− and Mfn2^−/− AEC2 cells after bleomycin treatment. a Scatterplot showing genes (orange) that are differentially expressed (adjusted p < 0.05) and have the same regulation direction in both Mfn1^−/− and Mfn2^−/− AEC2 cells after bleomycin treatment, compared to the control. b A functional enrichment map to show the common GO terms enriched on differentially expressed genes of Mfn1^−/− and Mfn2^−/− AEC2 cells after bleomycin treatment. c, d Heatmaps to show genes related to purine metabolism under the annotation purine ribonucleoside triphosphate metabolic process (GO: GO:0009205) (c) and genes related to lipid metabolism under the annotation fatty acid metabolic process (GO:0006631) (d), based on the functional enrichment results (b). e A functional enrichment map generated using genes differently expressed between Mfn1/2^−/− AEC2 cells and control AEC2 cells, using the threshold of an adjusted p < 0.05. f Differentially regulated genes related to glycolysis, asparagine (Asn) synthesis, de novo serine/glycine synthesis, and mitochondrial one-carbon metabolism in Sftpc^CreERT2+/+ versus MFN1/2^−/− AEC2 cells. For each gene, the fold change of FPKM is calculated relative to Sftpc^CreERT2+/+ control (G6P glucose-6-phosphate, G3P glyceraldehyde-3-phosphate, OAA oxaloacetate, Asp aspartate, Asn asparagine, 3P-OH-pyruvate 3-phosphohydropyruvate, P-ser 3-phosphoserine, Ser serine, Gly glycine, THF tetrahydrofolate, MTHF methyltetrahydrofolate, FTHF formyltetrahydropholate). The data are presented as mean±s.e.m. (NS not-significant; *adjusted p < 0.05, **adjusted p < 0.01, ***adjusted p < 0.001 vs. Sftpc^CreERT2+/+)